I
n the vasculature, reactive oxygen species (ROS), including superoxide (O 2 − ), hydrogen peroxide (H 2 O 2 ), and derivative oxygen radicals, are generated by the nicotinamide adenine dinucleotide phosphate oxidase (Nox) family of enzymes. 1 Of the 7 Nox family members, vascular and myeloid cells express Nox1, 2, 4, and 5 (*Nox5 gene is not present in rat and mouse genomes). 2 Although the importance of ROS to the obligate function of immune cells has been extensively defined, 3, 4 the physiological roles of the various Nox isoforms in the blood vessel wall remain largely enigmatic. 5 What is well known is that cardiovascular diseases promote increased ROS produc tion in blood vessels with the consequence of altered vaso motor tone, compromised endothelial function, and increased vascular cell proliferation and migration. 6, 7 Considerable insight has been gained into the posttransla tional regulation of Nox enzymes. 1, 8 The mechanisms involved vary significantly according to Nox isoform and cell type. The amount of ROS produced can also be regulated through changes in the gene expression of Nox isoforms and subunits. Many vasoactive, prohypertensive, and proproliferative hormones have been shown to increase the expression of Nox proteins via activation of wellcharacterized transcriptional networks. 1, 9, 10 In comparison, the mechanisms regulating the protein stability of the Nox isoforms are poorly understood. Previously we identified heat shock protein 90 (Hsp90) as a novel regulator of Nox5dependent ROS production. Loss of Hsp90 function through genetic or pharmacological approaches potently reduces Nox5dependent ROS production. 11 A chaperonedependent function of Hsp90 in controlling the folding of Nox5 is further supported by the loss of Nox5 expression in the presence of Hsp90 inhibition.
Hsps are abundant proteins that function as molecular chap erones. 12 Hsp90 regulates the function of ≈200 identified client proteins by influencing their 3dimensional structure and sta bility. 13 The majority of Hsp90 clients are transcription factors, kinases, or other signaling molecules such as the NO synthases. Figure 1 . Inhibition of heat shock protein 90 (Hsp90) in vitro and in vivo results in the loss of Nox isoform expression and reduced reactive oxygen species (ROS) production. A, COS-7 cells expressing Nox5 were treated with the Hsp90 inhibitor radicicol (RAD) at the indicated concentration for 24 h, and cell lysates were immunoblotted for hemagglutinin (HA)-nicotinamide adenine dinucleotide phosphate oxidase (Nox)5 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (loading control). B, Macrophages were isolated from C57BL/6 mice and were immunoblotted for Nox2 expression. RLU indicates relative light units; WT, wild type. Superoxide production was measured using L-012 chemiluminescence in phorbol 12-myristate 13-acetate (PMA) (100 nmol/L)-stimulated macrophages from C57Bl/6 and Nox2 14 Recently it has been shown that Hsp90 levels are elevated in both plaques and serum from individuals with atheroscle rosis. 15, 16 Inhibition of Hsp90 has been shown to suppress inflammation 15 and reduce ROS production in atherosclero sis, 17 but the mechanisms involved are poorly understood. A consequence of reduced Hsp90 activity is increased expres sion of Hsp70, 18 and the selective upregulation of Hsp70 itself has been shown to provide cardiovascular protection 19 suggesting that Hsp70 might mediate some of the beneficial effects of Hsp90 inhibition.
Thus, the major goals of this study were to determine whether the expression of other Nox proteins is regulated by Hsp90, to identify the role of Hsp70 in this process, and to identify the mechanisms of Nox protein degradation.
Materials and Methods

Cell Culture
COS7, HEK293, and promyelocytic leukemia cells (HL60) were grown in Dulbecco's Modified Eagle's medium as described. 11, 20 Human pulmonary artery endothelial cells and human aortic smooth muscle cells were from Cascade Biologics and grown in Endothelial Basal medium2 or Smooth Muscle Basal medium (Clonetics). Cells were transfected as described. 21 HemagglutininNox5 cell line was generated by flippase recombinasemediated integration (Invitrogen). Cells were exposed to different concentrations of RAD, 17AAG (Fisher Scientific), gel danamycin (Biosciences), geranylgeranylacetone (GGA), and MG132 (Sigma) for 0.5 to 24 hours. Bone marrow-derived macrophages from wild type and Nox2 −/− mice were obtained from Cell Biologics. Segments of intact human saphenous vein were obtained as discarded tissues. The procurement of these tissues conforms to the principles outlined in the Declaration of Helsinki and was approved by the Human Assurance Committee of the Georgia Health Sciences University.
Mouse Macrophage Isolation and Animal Studies
Male C57Bl/6 mice (7 to 10 weeks of age; Harlan, Indianapolis, IN) were used in all experiments. All animal studies were performed according to protocols approved by the Institutional Animal Care and Use Committee at Georgia Health Sciences University. Mouse macrophages were isolated from the peritoneum after injection of thioglycolate. In brief, 1 mL of thioglycolate was injected into each mouse 3 to 5 days before collection, peritoneal cells were collected by lavage, red blood cells lysed with hypotonic buffer, and isolated macrophages were cultured in complete Roswell Park Memorial Institute medium. Hsp90 inhibitors (17AAG, dissolved in 10% dimethyl sulfoxide, or 17[dimethylaminoethylamino]17demethox ygeldanamycin, dissolved in saline) were administered immunopre cipitated 16 to 24 hours before euthanization and isolation of lung tissue and blood.
DNA and Adenoviral Constructs
Plasmid DNAcoding Nox5β (AF325189), Nox1, Nox3, and Nox4 were described previously. 11, 20, 22 The complementary DNAs for myc CHIP, mycCHIP H260Q, and mycCHIP K30A were gifts from Dr Cam Patterson (University of North Carolina). Other cDNAs were obtained from Origene or Addgene. Control (red fluorescent protein) and HANox5 adenoviruses have been described.
22
Coimmunoprecipitation and Western Blotting Analysis
Cells were lysed on ice in 20mmol/L TrisHCl (pH 7.4), 1% Triton X100, 100mmol/L NaCl, 1mmol/L Na 3 VO 4 , 10mmol/L NaF, and 1% protease inhibitor cocktail (Sigma). Soluble extracts were incu bated for 2 hours at 4ºC with relevant antibodies: antiHA (Roche Applied Science), antiNox2 (Sigma), antiubiquitin (Cell Signaling Technology), and a negative isotype control mouse immunoglobulin (Santa Cruz Biotechnology), and complexes precipitated with protein A/G agarose (Santa Cruz Biotechnology). Western blotting was per formed as described previously 11 using antiHA (Roche), antiNox1, 2 (Sigma), antiHsp90, myc (BD Biosciences), antiubiquitin, anti green fluorescent protein, Hsp70 (Cell Signaling Technology), and antiCHIP. 
Real-Time Polymerase Chain Reaction
Realtime polymerase chain reaction was performed as described 24 using human Nox5β: 5'ccttctagttgcgcttttgc3' (sense) and 5'aatggagc cactgccatc3' (antisense), human 18S: 5'Cagccacccgagattgagca3' (sense) and 5'tagtagcgacgggcggtgtg3' (antisense).
Superoxide and Hydrogen Peroxide Measurement
The measurements of superoxide (L012) and hydrogen perox ide (Amplex Red) have been described. 11, 20, 22 2Hydroxyethidium (2OHE+), the specific product of the reaction of hydroethidine with superoxide radical anion (O2•−), was measured in HL-60 cells as described elsewhere 25 with recent modifications. 26 Tissue dihy droethidium staining was performed as described. 24 In brief, mouse aortas were treated with vehicle or RAD 20 µmol/L and embedded in optimal cutting temperature compound, sectioned, and incubated with dihydroethidium (5 μmol/L, Invitrogen).
Transient Knockdown of CHIP Gene With Small Interfering RNA
The with small interfering RNA (siRNA)targeting CHIP (STUB1, siRNA ID: s195025) was obtained from Applied Biosystems. Validated control and targeting siRNA were transfected into HEK293 cells stably expressing Nox5 and HL60 cells using siPORT Amine (Applied Biosystems).
Statistical Analysis
Data are reported as mean±SE, and statistical analyses were per formed using Instat and a 2tailed Student t test or ANOVA with a post hoc test where appropriate. Differences were considered as sig nificant at P<0.05. (HPAECs) were treated with the indicated concentration of RAD or vehicle for 24 h, and cell lysates were immunoblotted for Nox1, Nox2, and Nox4. E, Segments of human saphenous vein were incubated with RAD for 24 h and were immunoblotted for Nox1, Nox2, and Nox5 relative to GAPDH. F, C57BL/6 mice were treated with vehicle or with the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) (40 mg/kg) in saline. Mice were euthanized after 24 h, and lungs were isolated to determine the relative expression of Nox1 and Nox4. G, Blood was isolated from C57BL/6 mice treated with vehicle or with the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) (10 mg/kg for 16 h), and superoxide production was determined in leukocytes using L-012 chemiluminescence in response to PMA (100 nmol/L). H, ROS production was assessed in aortas from obese (db/db) mice using dihydroethidium (DHE) staining in the presence and absence of RAD (20 µmol/L, 24 h) normalized to collagen autofluorescence. Results are representative of at least 3 to 5 separate experiments, presented as mean±SE, *P<0.05 vs vehicle.
Results
Hsp90 Is Necessary for the Maintenance of Nox Protein Stability
To determine the effect of Hsp90 inhibition on the stability of other Nox family members, we incubated COS7 cells express ing Nox5, human pulmonary artery endothelial cells, murine macrophages, a human neutrophil cell line (HL60), and intact segments of human saphenous vein with Hsp90 inhibitors. We found that prolonged inhibition of Hsp90 robustly decreased the expression of Nox5 in COS7 cells, Nox2 in macrophages and neutrophils, Nox1 and Nox2 in human pulmonary artery endothelial cells, and Nox1, 2, and 5 in human saphenous vein ( Figure 1A-1E ). Expression of glyceraldehyde3phosphate dehydrogenase was not altered; densitometry for Figure 1D and 1E is shown in Figure I in the onlineonly Data Supplement. Hsp90 inhibitors reduced superoxide levels in WT macro phages but did not influence the dramatically reduced levels in Nox2 −/− mice ( Figure 1B , right). Hsp90 reduced super oxide levels in phorbol 12myristate 13acetate stimulated neutrophils as determined by 2OHE+ levels ( Figure 1C , right). In vivo, exposure of mice to the Hsp90 inhibitor 17(dimethylaminoethylamino)17demethoxygeldanamycin for 24 hours resulted in reduced Nox1 expression, but not Nox4, in the lung ( Figure 1F ; densitometry for Figure 1F is shown in Figure I in the onlineonly Data Supplement). In leu kocytes isolated from mice treated with 17AAG for 16 hours, there was a significantly reduced capacity to generate super oxide ( Figure 1G ). The upregulation of Hsp70 in leukocytes from mice treated with 17AAG is indicative of Hsp90 inhi bition ( Figure I in the onlineonly Data Supplement). Aortas from obese db/db mice exhibit higher dihydroethidium oxida tion levels in the media and adventitia versus that in lean mice ( Figure 1H ; Figure II in the onlineonly Data Supplement), and this was reduced in the presence of Hsp90 inhibitors.
Hsp90 Inhibition Promotes the Ubiquitination and Proteasomal Degradation of Nox5 and Nox2
To exclude the possibility that inhibition of Hsp90 decreases Nox5 protein expression via effects on human cytomegalovirus promoter activity or micro RNA levels, we first generated an additional expression vector. We found that RAD effectively decreased Nox5 expression driven by both CMV and EF1α promoters and did not alter micro RNA levels ( Figure II . Because these data suggest the involvement of the ubiquitinprotea some pathway, we next examined whether ubiquitin overex pression can promote Nox5 degradation. In cells transfected with ubiquitin and Nox5, we observed significant loss of Nox5 protein compared with cells in control ( Figure 2D ). To deter mine whether Nox5 is ubiquitin labeled, cells were treated with or without geldanamycin in the presence of MG132, and ubiquitinlabeled proteins were isolated by immunoprecipi tation. We observed increased ubiquitinlabeled Nox5 in the presence of Hsp90 inhibition ( Figure 2E ). These results were confirmed by reciprocal experiments immunoisolating Nox5 and blotting for ubiquitin ( Figure 2F and 2G).
Hsp70 Physically Associates With Nox and Is Important for Nox Activity and Stability
Inhibition of Hsp90 resulted in the upregulation of Hsp70 in vitro in cells ( Figure 3A ) and in vivo ( Figure I in the onlineonly Data Supplement). To determine whether Hsp70 is important for Nox5 regulation, we first tested whether Nox5 is a client protein of Hsp70 using coimmunoprecipitation. We found that Hsp70 physically associates with Nox5 ( Figure 3B ). To investi gate the effect of Hsp70 on Nox5 activity and protein stability in the absence of Hsp90 inhibition, we increased Hsp70 levels by cotransfection. Increased Hsp70 decreased Nox5 activity and promoted Nox5 degradation ( Figure 3C ). GGA, a nontoxic anti ulcer drug, has been shown to acutely increase Hsp70 expres sion. We exposed cells expressing Nox5 to GGA and found that upregulation of Hsp70 decreased Nox5derived superoxide in a time and dosedependent manner ( Figure 3D ; Figure III in the onlineonly Data Supplement). Cells treated with GGA exhibited increased binding of Hsp70 to Nox5 ( Figure 3E ). We also found that Hsp70 upregulation decreased Nox1 and Nox3 derived superoxide, but not Nox4derived hydrogen peroxide production ( Figure IV in the onlineonly Data Supplement). To determine whether Hsp70 is necessary for Nox5 degrada tion in response to Hsp90 inhibition, we silenced Hsp70 using a siRNA approach. In cells with diminished Hsp70 levels, there was a reduced ability of Hsp90 inhibitors to decrease Nox5 expression ( Figure 3F ).
CHIP Associates with Nox5
In the presence of Hsp90 inhibitors, we observed increased bind ing to Hsp70 and diminished binding to Hsp90 revealing a recip rocal pattern of chaperonedependent regulation ( Figure 4A ). In addition to Nox5, we also examined whether this pathway was operational in cells expressing Nox2 endogenously. Human peripheral blood mononuclear cells were treated with RAD and Nox2 was immunoprecipitated. Inhibition of Hsp90 resulted in reduced amounts of Hsp90 bound to Nox2 and increased Hsp70 binding ( Figure 4B ). We next assessed whether the Hsp70 interacting protein (CHIP), previously identified as a regulator of protein qualitycontrol of Hsp90dependent client proteins, binds to Nox proteins. CHIP has a tetratricopeptide repeat (TPR) domain at its N terminus, which interacts with Hsp70, and a Ubox domain at its C terminus, which contains an E3 ubiqui tin ligase. To examine whether CHIP physically associates with Nox5, cells were cotransfected with HANox5 and myctagged CHIP wild type or mutants: CHIP H260Q (a Ubox domain mutant) and CHIP K30A (a TPR domain mutant). Using a co immunoprecipitation approach, we found a strong association between both the wildtype and the E3 ubiquitin ligase-deficient CHIP mutant (H260Q), whereas CHIP lacking an intact TPR domain did not associate with Nox5 ( Figure 4C ). These data suggest that CHIP incorporation into Nox complexes is through interaction with the TPR recognition motif of Hsp70. , and cell lysates were collected after 12 h and analyzed by Western blot. C, Human neutrophils (HL-60) were incubated with or without RAD (5 µmol/L) and MG-132 for 12 h, and lysates were immunoblotted for Nox2 vs Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). D, COS-7 cells were cotransfected with Nox5 and either a control (RFP) or HA-ubiquitin. Forty-eight hours later, cell lysates were immu noblotted for Nox5, hemagglutinin (HA)-ubiquitin, and GAPDH. E, COS-7 cells expressing HA-Nox5 were exposed to vehicle or geldanamycin (GA; 1 µmol/L) and MG-132 (5 μg/mL) for 12 h. Cell lysates were immunoprecipitated (IP) using either a negative isotype control mouse immunoglobulin (IgG) or an anti-ubiquitin(Ub) antibody. Immune complexes were immunoblotted for ubiquitin or HA-Nox5. F and G, COS-7 cells were cotransfected with HA-Nox5 and green fluorescent protein (GFP)-ubiquitin and were exposed to GA (1 μmol/L) and 132: Z-LLL-CHO (MG)-132 (5 μg/mL) for 12 h. Cell lysates were immunoprecipitated using anti-HA, and immune complexes were immunoblotted for HA-Nox5 or GFP-ubiquitin. Results are representative of ≤3 separate experiments. Real-time PCR data are expressed as percentage of 18S (mean±SE, n=6). Ct indicates cycle threshold.
CHIP Induces the Degradation of Nox5 and Reduces Superoxide Production
Increased expression of CHIP, but not either of the CHIP mutants, dosedependently decreased Nox5dependent ROS production and protein expression ( Figure 5A-5F ). To broaden the functional significance of CHIP in regulating the activity and stability of other Nox isoforms, we transfected CHIP together with Nox1, Nox3, and Nox4 and found that CHIP decreased the activity of Nox1 and Nox3, whereas ROS production from Nox4 was unaffected ( Figure IV in the onlineonly Data Supplement). The increased expression of wildtype CHIP promoted Nox5 ubiquitination, an effect that was absent in cells expressing either of the CHIP mutants ( Figure 5G ). To determine for the role of endogenous CHIP in the degradation of Nox proteins, we silenced CHIP expression using siRNA ( Figure 6A ). Reduced expression of CHIP abrogated the degradation of Nox5 induced by Hsp90 inhibitors (Figure 6B and 6C) . Further, the ability of Hsp90 inhibitors to induce Nox5 ubiquitination was reduced in cells with diminished levels of CHIP ( Figure 6D and 6E) . To determine whether CHIP is necessary to mediate the effects of increased Hsp70 expression on Nox5 activity, we silenced CHIP and induced Hsp70 expression in cells expressing Nox5. In cells treated with a control siRNA, GGA decreased the ability of Nox5 to generate superoxide. In contrast, cells treated with CHIP siRNA reduced the expression levels of CHIP, and super oxide production was unaffected by GGA treatment ( Figure 6F ). We also investigated whether CHIP can regulate the expression of other Nox enzymes. In a human neutrophil cell line, silencing CHIP reduced the ability of Hsp90 inhibition to decrease endog enous Nox2 expression ( Figure 6G ). In addition to CHIP, there are multiple chaperoneassociated E3 ubiquitin ligases, includ ing Cullin5, valosincontaining protein, Parkin, and MDM2 that are stimulated by the inhibition of Hsp90 
Discussion
Hsp90 and cochaperones regulate the tertiary structure of select client proteins such as nuclear receptors, kinases, and NO synthases to enable specific enzyme functions. 12 We have previously shown that the binding of Hsp90 to Nox5 regulates ROS production, 11 and the current study shows that the pro tein expression of Nox1, Nox2, and Nox5 depends on active Hsp90. Inhibition of Hsp90 both in vitro and in vivo reduced Nox expression and ROS production in isolated leukocytes, lung tissue, human blood vessels, and aorta from db/db mice. These results support the hypothesis that Hsp90 is integral to the function and stability of the Nox family of enzymes.
One exception to this paradigm was the inability of Hsp90 inhibitors to alter Nox4 expression and activity. We have previ ously found that the Cterminal region of Nox5 mediates the binding to Hsp90, and in domainswapping experiments we have shown that the equivalent region in Nox4 is sufficient to provide resistance to Hsp90 inhibitors in Nox enzymes that are otherwise sensitive. 11 Expression levels of p22phox can influ ence the stability of Nox proteins, but the inability of p22phox to influence Nox5, which is sensitive to Hsp90 inhibitors and the lack of effect of Hsp90 inhibitors on p22phox levels, suggest that indirect regulation via p22phox is not a major mechanism. The insensitivity of Nox4 to Hsp90 inhibition suggests that functions conferred by Hsp90 binding to other Nox enzymes are not needed for Nox4. Indeed, Nox4 has enzymatic charac teristics unique from the other family members. It is regarded as constitutively active 31, 32 and emits only detectable hydrogen peroxide instead of superoxide. 33, 34 The mechanisms by which Hsp90 supports the stimulusdriven activity of Noxes 1, 2, 3, and 5 and the release of superoxide remain to be determined.
The upregulation of Hsp70 is a welldescribed outcome of Hsp90 inhibition and is mediated by the loss of Hsp90dependent repression of HSF1. 18 To delineate a distinct role for Hsp70 in the absence of Hsp90 inhibition, we increased Hsp70 levels via transfection of a GFPtagged transgene. We found that the elevation of Hsp70 expression alone reduced ROS production from Nox5 and decreased Nox5 expression. These results sug gest a direct interaction between Hsp70 and Nox5, and in CoIP experiments we indeed found that Hsp70 binds to Nox5. This is the first evidence that Hsp70 is an essential component of Nox complexes. In addition to Nox5, we also found that Hsp70 decreases ROS production from Nox1 and Nox3, but not Nox4, and that Hsp70 binds to Nox2. These results further suggest that Hsp70 is a negative regulator of other Nox enzymes, and there is considerable evidence in the literature to support the protec tive role of Hsp70 against oxidative damage 35, 36 and the ability to negatively regulate Nox enzyme stability, and ROS produc tion may contribute, at least in part, to the beneficial effects of Hsp70. These data are supported by previous studies show ing that chemical or thermal induction of Hsps in neutrophils reduces ROS production. 37 Mitogens and the protein kinase C agonist, PMA, have been shown to activate Noxes 1, 2, 3, and 5, and the ability of these stimuli to upregulate Hsp70 38 would also provide a mechanism for feedback inhibition. This feedback inhibition can be taken further because ROS themselves are potent inducers of Hsp70 expression, 39 which would promote a reduction in nicotinamide adenine dinucleotide phosphate dependent ROS production.
Protein quality control is a vital process that determines whether proteins are properly folded and targets misfolded proteins for degradation. Molecular chaperones, including Hsp90, Hsp70, and cochaperones, are important contributors to protein quality control. 40 Hsp90 regulates the folding and func tion of >200 known client proteins, and inhibition of Hsp90 promotes the degradation of many of these clients, including protein kinase B, phosphoinositide dependent kinase, NO syn thases, glucocorticoid receptor, soluble guanylate cyclase, and cysticfibrosis transmembraneconductance regulator. 23, [41] [42] [43] [44] Decreased function of Hsp90 results in the upregulation of Hsp70, which recruits specialized chaperonedirected ubiqui tin ligases to promote client protein ubiquitination and degra dation. 40 Our current study shows that both Hsp90 and Hsp70 bind to Nox5, suggesting distinct roles for Hsp90 and Hsp70 in the regulation of Nox protein activity and stability. In the presence of Hsp90 inhibitors, we found a decreased association between Nox5 and Hsp90 and increasing binding to Hsp70. These data indicate that the ratio of Hsp90 and Hsp70 bound to Nox proteins is a critical mechanism regulating ROS produc tion. Disruption of the Hsp90:Nox interaction or facilitation of the Hsp70:Nox interaction may be an effective strategy to suppress Noxderived ROS and might have a clinical benefit in cardiovascular disease and inflammation.
The results of our study also indicate that ubiquitination is a novel and important posttranslational modification of Nox5 and that the ubiquitinproteasome pathway regulates Nox5 degradation. The ubiquitination of proteins is orchestrated by ≤3 types of enzymes: an E1 ubiquitinactivating enzyme, an E2 ubiquitinconjugating enzyme, and an E3 ubiquitin ligase. The E3 ubiquitin ligases catalyze the transfer of ubiquitin to substrate proteins which are then recognized by the proteasome and degraded. The E3 ubiquitin ligases are a large and diverse family of enzymes and there are several, including CHIP, Cullin5, valosincontaining protein, Parkin, and MDM2 that have been shown to be regulated by December 2012 molecular chaperones. [27] [28] [29] [30] The best characterized of these, CHIP, possesses a TPR domain at its N terminus, which interacts with molecular chaperones Hsp70/90, and a Ubox domain at its C terminus, which contains an E3 ubiquitin ligase domain. Both the TPR and Ubox domains of CHIP are necessary for the degradation of Hsp90 client proteins. 23, [41] [42] [43] [44] [45] However, CHIP does not promote the degradation of all clients of Hsp90. It promotes the partitioning of endothelial NO synthase from a soluble to an insoluble and inactive cellular compartment, 46 and more surprisingly, in fibroblasts, it can increase the refolding of proteins via its TPR domain. 42 We found that CHIP associates in a complex with Nox5 and regulates the activity and stability of Nox5 and Nox2. Both the TPR and Ubox domains of CHIP are necessary to induce the degradation of Nox5, which suggests that this process is chaperone dependent. Other chaperonedependent E3 ligases, Cullin5, valosincontaining protein, Parkin, and MDM2 did not appear to play a major role in the regulation of Nox protein stability. Collectively, these data demonstrate that chaperone and CHIPdependent ubiquitination is a novel mechanism regulating Nox activity and stability.
Despite significant advances in the therapeutic approach, cardiovascular diseases remain the leading cause of mor bidity and mortality in the United States. 47 Elevated Hsp90 levels in individuals with atherosclerosis 15, 16 would be sup portive of increased Nox activity and ROS production and contrast from the known protective effects of Hsp70 against oxidative damage and ROS levels. We found that altering the balance of Hsp90 to Hsp70 bound to Nox5 could alter protein stability and ROS production. In blood vessels from animal models of obesity and type II diabetes mellitus, elevated ROS levels secondary to increased Nox1 mediate dysfunction of the endothelium and impaired vasomotor control. 24 We found that inhibition of Hsp90 reduces ROS production in blood vessels of both lean and obese mice. Although Hsp90 inhibitors have been shown to be power ful antiinflammatory agents and reduce ROS production in atherosclerosis, clinical efficacy is constrained by side effects. This is not surprising given the multitude of proteins regulated by Hsp90 including endothelial NO synthase 48 and soluble guanylate cyclase, 49 which mediate endothelium dependent relaxation. Therefore, a greater understanding of the mechanisms involved would enable more selective approaches to targeting Hsp90 client proteins and more effective therapeutics for the treatment of inflammation and cardiovascular diseases.
Conclusions
This study reveals a novel mechanism regulating the activity and stability of Nox proteins via the molecular chaperones, Hsp90 and Hsp70. The ratio of Hsp90 and Hsp70 bound to Nox proteins is a critical mechanism regulating the proper folding and ROS production and guides Nox protein triage decisions. Accordingly, disruption of the Hsp90:Nox interac tion or facilitation of Hsp70:Nox binding might be an effective strategy to suppress ROS. We have also identified ubiquitina tion as a novel mechanism and an important posttranslational modification of Nox proteins that is regulated, at least in part, by the molecular chaperone and cochaperone CHIP. Further studies are necessary to elucidate the significance of this path way in disease conditions.
